T-cell acute lymphoblastic leukemia

Last updated
T-cell acute lymphoblastic leukemia
T-ALL cells.jpg
T-lymphoblastic cells of acute leukemia in the bone marrow. In some cases, the cytoplasm is concentrated at one pole of the cell, forming "hand mirror cells".
Specialty Haematology, oncology
Symptoms Recurrent infections, unusual or common bleeding and bruising, extreme tiredness, unexplained fever, unexplained weight gain, swollen lymph nodes
Usual onsetMost prevalent in the adult population with incidences[ spelling? ] diminishing with age. Amongst pediatric population, median onset of age 9. Marked male predominance [1]
CausesCurrently unknown
Diagnostic method Blood test, bone marrow aspiration, [2] biopsy, CT, MRI, lumbar puncture, [2] genetic testing
TreatmentLong-term chemotherapy, [3] CNS radiation therapy, [1] stem cell transplantation [4]
Prognosis 5-Year Event Free Survival: 70%, Overall Survival: 80% [1]
Frequency7% at ages 1-10, 14% at ages 10-15, and 29% at ages 15-18 [5]

T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the bone marrow. [6] Acute lymphoblastic leukemia (ALL) is a condition where immature white blood cells accumulate in the bone marrow, subsequently crowding out normal white blood cells [7] and create build-up in the liver, spleen, and lymph nodes. [8] The two most common types of ALL are B-lymphocytes and T-lymphocytes, where the first protects the body against viruses and bacteria through antibody production which can directly destroy target cells or trigger others to do so, whilst the latter directly destroy bacteria or cells infected with viruses. [9] Approximately 20% of all ALL patients are categorized specifically to suffer from T-ALL and it is seen to be more prevalent in the adult population in comparison to children, with incidences[ spelling? ] shown to diminish with age. [6] [10] Amongst T-ALL cases in the pediatric population, a median onset of age 9 has been identified and the disease is particularly prominent amongst adolescents. [6] The disease stems from cytogenic and molecular abnormalities, resulting in disruption of developmental pathways controlling thymocyte development, tumor suppressor development, and alterations in control of cell growth and proliferation. [1] Distinct from adult T-cell leukemia where T-cell lymphotropic virus Type I causes malignant maturation of T-cells, T-ALL is a precursor for lymphoid neoplasm. [6] Its clinical presentation most commonly includes infiltration of the central nervous system (CNS), and further identifies mediastinal mass presence originating from the thymus, along with extramedullary involvement of multiple organs including the lymph node as a result of hyperleukocytosis.

Contents

Signs and symptoms

T-ALL patients may not always experience all the signs and symptoms below. Patients with other medical conditions that are not leukemia may also experience similar symptoms.

Clinical manifestations

Originating from epigenetic and genetic alterations in immature thymocytes, T-ALL is a highly aggressive and heterogenous disease. Patients often present extensive bone marrow involvement, mediastinal mass, adenopathy, CNS involvement, and splenomegaly. [1] Symptoms can be presented acutely or develop progressively over time. The most common clinical feature amongst patients is the proliferation of malignant clones, hence suppressing normal hematopoiesis, resulting in deficiency of functioning peripheral blood cells (particularly thrombocytes) deficiency. [1]

Risk factors

T-ALL is not a contagious nor inherited condition. Its two main risk factors are age and gender. [8] Most cases of leukemia increase with age, with ALL being the main exception, which peaks in children aged 2 to 5 years. T-ALL is seen to be most prevalent in the adult population, but amongst cases in the pediatric population, it is seen to have a median onset of age 9 and is most prominent to adolescents. [6] [10] The disease also is marked male predominance with a three-fold increased risk of developing T-ALL in comparison to females. It is currently unclear as to why T-ALL is preferential towards older children and males. [1]

Cytogenetics

Basic karyotyping showed structural chromosomal rearrangements in 50-75% of T-ALL patients, primarily inversion and translocations. [1] Diagnostic yield can be substantially increased through further diagnosis through fluorescent in situ hybridization (FISH) and other various molecular technologies, for example single nucleotide polymorphism (SNP) array. The most common structural abnormality is rearrangement of the TCR gene. 95% of T-cell TCR consist of an alpha and beta chain (encoded by TRA and TRB, respectively), where only 5% of T-cell TCR consists of gamma and delta chains (encoded by TRG and TRD, respectively). [4]

Karyotyping showed that TRD and TRB undergo recombination most commonly, whereas TRA is seldom involved and TRG is rarely rearranged. These rearrangements affect the normal process of TCR and could lead to cellular machinery failing to correctly repair recombination-activating RAG protein induced double-strand breaks. [1] All 30 genes known to illegitimately recombine with TCR genes function primarily to regulate epigenetics through roles such as signal transducers, transcription factors (tumor suppressors or oncogenes), cell cycle regulators, or ribosomal proteins.

T-Cell TCR encoded by TRA, TRD, and TRG at chromosome bands 14q11 and 7q34 become malignant in T-ALL patients. [1] The build-up of malignant T-cells in T-ALL are clones with identical T-cell receptor gene arrangements having taken rise from a single cell. The gene rearrangements, as a result of the malignant cell, juxtapose both TCR genes and other critical genes that code for transcription factors. This results in dysregulation of partner gene transcription, which serves as the main cause of leukemogenesis – a multi-step process of induction, development, and progression of leukemic diseases. [1] 20% of all leukemias demonstrate simultaneous rearrangement of these genes.

Pathology

Like most cancers, mutations in the DNA begin T-ALL development and lead to loss of function of white blood cells. Different subtypes of leukemia have similarities in their causes, which are a combination of genetics, epigenetic changes, and environmental factors. However, because there are few T-ALL cases in comparison to other subtypes of leukemia, there is currently no clear cause of T-ALL. T-ALL is not contagious nor inherited but specific genetic mutations, commonly including NOTCH1 and CDKN2A, may be passed along which increases susceptibility of T-ALL. [10]

Causes of T-ALL

Genetic conditions

Some patients may have familial histories with leukemia predispositions which increases risk of developing T-ALL. Li–Fraumeni syndrome is an inherited condition that leads to mutation of TP53, a tumor suppressor gene, which then increases risk of T-ALL. Mutation in gene SPRED1 is also associated with development of T-ALL.

Patients with immature thymocytes in the thymus begins T-ALL development. Furthermore, hereditary conditions such as Down syndrome, neurofibromatosis type 1, ataxia telangiectasia, and Noonan syndrome are associated with higher risk of developing T-ALL.

Radiation exposure

Human T-Lymphotropic Virus

Those who have had previous chemotherapy and exposure to radiation may have increased risks of developing T-ALL. CDKN2A is an inherited polymorphism variant that is seen to be associated with development of T-ALL. SR-90 emission from nuclear reactor accidents is also believed to increase risk of developing T-ALL.

Chemical exposure

Benzene, a chemical classified as being carcinogenic to humans, is associated with increased risk of T-ALL, as well as other forms of leukemia. [12]

Viruses

Human T-lymphotropic virus (HTLV-1) is a retroviral infection that affect white blood cells (T-cells), which may later develop into T-ALL and other subtypes of leukemia. [13]

Diagnosis

When doctors are suspicious of a patient potentially suffering from T-ALL after careful examination of background (including medical history, signs, and symptoms), doctors would then conduct tests, procedures, and scans to proceed with diagnosis of T-ALL. Some symptoms and medical history may not be specific enough to diagnose T-ALL, so further testing may be required. Doctors may consider some factors mentioned but would not necessarily conduct all tests possible. [11]

Assessments

Blood tests

Complete blood count (CBC) is done to test for T-ALL by measuring the different types and maturity of cells in the patient's blood, which allows the donor to determine whether leukemic cells are present in the patient. Additionally, blood tests that show high levels of white blood cells or low levels of red blood cells may also be a sign of T-ALL. Further testing could also help indicate whether T-ALL has affected other organs such as the kidneys as well as the genetic alterations of the disease.

Bone marrow aspiration and biopsy

Bone marrow consists of a combination of solid and liquid components. Bone marrow aspiration and biopsies are typically done simultaneously to help determine and confirm the type and severity of T-ALL. Further biopsies such as skin and lymph node biopsies may also need to be done to check for the spread of T-ALL. [2]

X-rays and ultrasound

As swollen spleen and lymph nodes are symptoms of T-ALL, X-rays and ultrasound scans, such as CT and MRI, can help confirm the diagnosis. This also provides information on the impact T-ALL has on other organs of the body.

Lumbar puncture

To prevent ineffective treatments towards T-cells that have invaded the CNS, lumbar puncture allows doctors to determine whether the treatments will be effective. This also reveals the spread of T-ALL. [2]

Lumbar Puncture Positions Blausen 0617 LumbarPuncture.png
Lumbar Puncture Positions

Genetic test

Genetic testing helps identify chromosomal abnormalities in the patients. This can help identify the genetic mutations and therefore diagnose the specific leukemia subtype.

Staging

Normal staging is not used for T-ALL because it is already spread throughout the body when first diagnosed. However, they have their own system of classifying T-ALL cases. [14] First, patterns of gene expression are investigated to define T-ALL. Then, stages of thymic development can be determined by identifying specific expressions in chromosomal abnormalities. This forms the stages of T-ALL cases being either at high or low risk. [8] Patients will then receive the appropriate treatment in respect to whichever class they are in. [14]

Treatment

Currently, standard treatment of T-ALL takes the form of long-term chemotherapy and drug intake to prevent or treat side effects associated with low white blood cell count as a result of intensive chemotherapy regimes. The treatment typically takes place over three stages: induction, consolidation, and maintenance. [3] Treatment is expected to span over approximately two years with the maintenance phase lasting the longest. T-ALL can spread to areas of the brain and spinal cord, [2] which can be diagnosed through lumbar puncture assessment in patients suspected to suffer from T-ALL. Lumbar puncture helps to identify leukemic cells surrounding the cerebrospinal fluid (CSF). [3] Even if leukemic cells are not found in the CSF at the time of diagnosis, it is highly likely that they will spread there with time and progression of the disease. Henceforth, prophylactic intrathecal chemotherapy in CNS lymphoma, a treatment to lower risk of leukemia spreading to the spinal cord and brain by directly administering chemotherapy to the CSF, is crucial. [3]

In comparison to B-ALL, T-ALL patients present more high-risk features including tendency for earlier relapse, CNS involvement, and resistance to chemotherapy. In response, Prophylactic Intrathecal Chemotherapy is further enhanced with CNS radiation therapy. [1] In treating high-risk T-ALL patients, allogeneic hematopoietic stem cell transplantation has been deemed to produce highly successful and promising results. However, its consequence includes increased relapse, which reduces its curative potential. Patients undergoing transplantation must be continuously monitored for minimal residual disease (MRD), usually via qPCR analysis of T-cell receptor (TCR) genes to evaluate for fusion transcripts such as SIL-TAL1. [15] Mutation of TAL1 is frequently present in T-ALL patients, where SIL/TAL1 fusion gives rise to inappropriate TAL1 expression, in turn promoting T-cell leukemogenesis. [4] The analysis is critical to ensure that immediate intervention is taken during early stages of relapse.

Young T-ALL patients showed significant improvement through multimodal therapy, involving initial induction therapy – including a glucocorticoid, vincristine, L-asparaginase, and an anthracycline – for 4 to 6 weeks, intensive combination therapy for 6–8 months, lastly 18–30 months of low-intensity anti-metabolite-based therapy. [8] It is crucial to note the importance of differential treatment amongst youth and adults. Studies have shown that through administering a random variation of either traditional pediatric scheme or intensive block-based chemotherapy, the two groups showed significantly different responses. [4] Although both treatments included administering high-dose methotrexate and asparaginase and allogeneic hematopoietic stem cell transplantation, high survival and low death rates were present for all patients for the first treatment whereas the latter led to a high toxic death rate amongst adults. [16]

Prognosis

In childhood, T-ALL patients can expect a 5-year event free survival and overall survival of, respectively, 70% and 80%. [1] Amongst approximately 25% of children who relapse, survival rate sits at 30-50% and the patients show much poorer prognosis. [1] Monitoring for MRD is critical as previously mentioned, through qPCR analysis, in order to evaluate the efficacy of treatment.

Recent genomic studies have found that a selection of genetic variants in relation to clonal evolution that drive resistance have been found as the basis for T-ALL relapse. Over 20% of patients with relapsed T-ALL showed mutation in the variant cytosolic 5’-nucleotidase II (NT5C2) gene, while the TFDP3 gene has also been found to confer chemoresistance in children. [1]

Epidemiology

Although over 100 genes mutations have been identified in T-ALL patients, only NOTCH1 and CDKN2A mutations are considered to be common. [13]

In over 50% of pediatric T-ALL cases, mutations in epigenetic regulators have been identified. [5] This activates mutations of NOTCH1 and FBXW7 causes the tumor-suppressing gene to lose its functions, leading to T-ALL. [17]

Near-telomeric location may sometimes generate subtle exchanges in DNA material at the loci involved in oncogenic rearrangements of T-ALL. This causes cryptic translocation and therefore deletes the putative tumor suppressor gene CDKN2A (INK4A). At the same time, TLX1 and NOTCH1 may also be activated at higher frequency than usual. The multistep prognosis of T-ALL has hence been said to intensify and rapidly progress due to accumulation of effects resulting from dysregulation of multiple signaling pathways. [5]

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name usually refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Medical condition

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Acute lymphoblastic leukemia</span> Blood cancer characterised by overproduction of lymphoblasts

Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated. Treatment for ALL often involves chemotherapy, radiation therapy, stem cell transplantation, or a combination of these approaches.

<span class="mw-page-title-main">Acute promyelocytic leukemia</span> Subtype of acute myeloid leukaemia characterised by accumulation of promyelocytes

Acute promyelocytic leukemia is a subtype of acute myeloid leukemia (AML), a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARA) gene and is distinguished from other forms of AML by its responsiveness to all-trans retinoic acid therapy. Acute promyelocytic leukemia was first characterized in 1957 by French and Norwegian physicians as a hyperacute fatal illness, with a median survival time of less than a week. Today, prognoses have drastically improved; 10-year survival rates are estimated to be approximately 80-90% according to one study.

<span class="mw-page-title-main">Myeloid sarcoma</span> Medical condition

A myeloid sarcoma is a solid tumor composed of immature white blood cells called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow.

Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name. Such diseases are all lymphoproliferative disorders. Most lymphoid leukemias involve a particular subtype of lymphocytes, the B cells.

<span class="mw-page-title-main">Follicular lymphoma</span> Medical condition

Follicular lymphoma (FL) is a cancer that involves certain types of white blood cells known as lymphocytes. The cancer originates from the uncontrolled division of specific types of B-cells known as centrocytes and centroblasts. These cells normally occupy the follicles (nodular swirls of various types of lymphocytes) in the germinal centers of lymphoid tissues such as lymph nodes. The cancerous cells in FL typically form follicular or follicle-like structures (see adjacent Figure) in the tissues they invade. These structures are usually the dominant histological feature of this cancer.

<span class="mw-page-title-main">Acute myeloid leukemia</span> Cancer of the myeloid line of blood cells

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly, and is typically fatal within weeks or months if left untreated.

Juvenile myelomonocytic leukemia (JMML) is a rare and serious chronic leukemia (cancer of the blood) that affects children mostly aged 4 and younger. The name JMML now encompasses all diagnoses formerly referred to as juvenile chronic myeloid leukemia (JCML), chronic myelomonocytic leukemia of infancy, and infantile monosomy 7 syndrome. The average age of patients at diagnosis is 2 years old. The World Health Organization has included JMML in the category of myelodysplastic and myeloproliferative disorders.

<span class="mw-page-title-main">ETV6</span> Protein-coding gene in the species Homo sapiens

ETV6 protein is a transcription factor that in humans is encoded by the ETV6 gene. The ETV6 protein regulates the development and growth of diverse cell types, particularly those of hematological tissues. However, its gene, ETV6 frequently suffers various mutations that lead to an array of potentially lethal cancers, i.e., ETV6 is a clinically significant proto-oncogene in that it can fuse with other genes to drive the development and/or progression of certain cancers. However, ETV6 is also an anti-oncogene or tumor suppressor gene in that mutations in it that encode for a truncated and therefore inactive protein are also associated with certain types of cancers.

Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or other tissues while SLL is the infiltration of these malignant B lymphocytes into lymphatic and/or other tissues with little or no circulation of these cells in the blood. CLL along with its SLL variant are grouped together in the term CLL/SLL.

Minimal residual disease (MRD) is the name given to small numbers of leukaemic cells that remain in the person during treatment, or after treatment when the patient is in remission. It is the major cause of relapse in cancer and leukemia. Up until a decade ago, none of the tests used to assess or detect cancer were sensitive enough to detect MRD. Now, however, very sensitive molecular biology tests are available, based on DNA, RNA or proteins. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells.

<span class="mw-page-title-main">Acute megakaryoblastic leukemia</span> Medical condition

Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. Megakaryoblasts are the most immature precursor cells in a platelet-forming lineage; they mature to promegakaryocytes and, ultimately, megakaryocytes which cells shed membrane-enclosed particles, i.e. platelets, into the circulation. Platelets are critical for the normal clotting of blood. While malignant megakaryoblasts usually are the predominant proliferating and tissue-damaging cells, their similarly malignant descendants, promegakaryocytes and megakaryocytes, are variable contributors to the malignancy.

Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. It is a subtype of "leukemia of ambiguous lineage".

<span class="mw-page-title-main">Blastic plasmacytoid dendritic cell neoplasm</span> Medical condition

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

<span class="mw-page-title-main">Childhood leukemia</span> Medical condition

Childhood leukemia is leukemia that occurs in a child and is a type of childhood cancer. Childhood leukemia is the most common childhood cancer, accounting for 29% of cancers in children aged 0–14 in 2018. There are multiple forms of leukemia that occur in children, the most common being acute lymphoblastic leukemia (ALL) followed by acute myeloid leukemia (AML). Survival rates vary depending on the type of leukemia, but may be as high as 90% in ALL.

Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer. Radiation therapy is commonly used to treat known tumor occurrence in the brain, either with highly precise stereotactic radiation or therapeutic cranial irradiation. By contrast, PCI is intended as preemptive treatment in patients with no known current intracranial tumor, but with high likelihood for harboring occult microscopic disease and eventual occurrence. For small-cell lung cancer with limited and select cases of extensive disease, PCI has shown to reduce recurrence of brain metastases and improve overall survival in complete remission.

Pediatric-type follicular lymphoma (PTFL) is a disease in which malignant B-cells accumulate in, overcrowd, and cause the expansion of the lymphoid follicles in, and thereby enlargement of the lymph nodes in the head and neck regions and, less commonly, groin and armpit regions. The disease accounts for 1.5% to 2% of all the lymphomas that occur in the pediatric age group.

Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL).

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Pediatric T-Cell Acute Lymphoblastic Leukemia". atlasgeneticsoncology.org. Retrieved 2020-04-07.
  2. 1 2 3 4 5 "Acute lymphoblastic leukemia (ALL): Symptoms, causes, and treatment". www.medicalnewstoday.com. 14 October 2019. Retrieved 2020-04-07.
  3. 1 2 3 4 "Typical Treatment of Acute Lymphocytic Leukemia (ALL)". www.cancer.org. Retrieved 2020-04-07.
  4. 1 2 3 4 D’Angiò, Mariella; Valsecchi, Maria G.; Testi, Anna M.; Conter, Valentino; Nunes, Vittorio; Parasole, Rosanna; Colombini, Antonella; Santoro, Nicola; Varotto, Stefania; Caniglia, Maurizio; Silvestri, Daniela (January 2015). "Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group". Haematologica. 100 (1): e10–e13. doi:10.3324/haematol.2014.112151. ISSN   0390-6078. PMC   4281327 . PMID   25304610.
  5. 1 2 3 "T-lineage acute lymphoblastic leukemia (T-ALL)". atlasgeneticsoncology.org. Retrieved 2020-04-07.
  6. 1 2 3 4 5 Litzow, Mark R.; Ferrando, Adolfo A. (2015-08-13). "How I treat T-cell acute lymphoblastic leukemia in adults". Blood. 126 (7): 833–841. doi: 10.1182/blood-2014-10-551895 . ISSN   0006-4971. PMID   25966987.
  7. ↑ "Acute Lymphoblastic Leukemia (ALL)". www.stjude.org. Retrieved 2020-04-07.
  8. 1 2 3 4 "T-cell Acute Lymphoblastic Leukaemia". Leukaemia Care. Retrieved 2020-04-07.
  9. ↑ "What is the Difference Between B-cell Lymphoma and T-cell Lymphoma?". Dana-Farber Cancer Institute. 18 Jun 2019. Retrieved 7 Apr 2020.
  10. 1 2 3 "T-Cell Acute Lymphoblastic Leukemia - My Cancer Genome". www.mycancergenome.org. Retrieved 2020-04-07.
  11. 1 2 "Leukemia - Chronic T-Cell Lymphocytic - Stages". Cancer.Net. 2012-06-25. Retrieved 2020-04-07.
  12. ↑ Khalade, Abdul; Jaakkola, Maritta S.; Pukkala, Eero; Jaakkola, Jouni J. K. (2010-06-28). "Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis". Environmental Health: A Global Access Science Source. 9: 31. doi:10.1186/1476-069X-9-31. ISSN   1476-069X. PMC   2903550 . PMID   20584305.
  13. 1 2 "Human T-cell leukemia virus type 1 | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2020-04-07.
  14. 1 2 "Acute lymphocytic leukemia - Diagnosis and treatment - Mayo Clinic". www.mayoclinic.org. Retrieved 2020-04-07.
  15. ↑ D’Angiò, Mariella; Valsecchi, Maria G.; Testi, Anna M.; Conter, Valentino; Nunes, Vittorio; Parasole, Rosanna; Colombini, Antonella; Santoro, Nicola; Varotto, Stefania; Caniglia, Maurizio; Silvestri, Daniela (2015-01-16). "Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group". Haematologica. 100 (1): e10–e13. doi:10.3324/haematol.2014.112151. ISSN   0390-6078. PMC   4281327 . PMID   25304610.
  16. ↑ Quist-Paulsen, P.; Toft, N.; Heyman, M.; Abrahamsson, J.; Griškevičius, L.; Hallböök, H.; Jónsson, Ó G.; Palk, K.; Vaitkeviciene, G.; Vettenranta, K.; Åsberg, A. (2020-02-20). "T-cell acute lymphoblastic leukemia in patients 1–45 years treated with the pediatric NOPHO ALL2008 protocol". Leukemia. 34 (2): 347–357. doi:10.1038/s41375-019-0598-2. ISSN   1476-5551. PMID   31611626. S2CID   204459614.
  17. ↑ Belver, Laura; Ferrando, Adolfo (2016-08-30). "The genetics and mechanisms of T cell acute lymphoblastic leukaemia". Nature Reviews Cancer. 16 (8): 494–507. doi:10.1038/nrc.2016.63. ISSN   1474-1768. PMID   27451956. S2CID   28636912 . Retrieved 2020-04-05.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.